OTC· Pharmaceutical Preparations· Inc. A1· CIK 0001771706

VREOF

Vireo Growth Inc.
$9.61 ▼ -2.44%
Prev close $9.85
12-mo target$45.00 (+368.3%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on VREOF right now — valuation, ownership and activity at a glance.
SEC Reports
13
Price chart 30d -11.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 3, 2026 ftd
FTD: VREOF — 69,984 shares ($0.8M) failed to deliver
Settlement: 20260903, Price: $10.80, FTD Value: $755,827.2, VIREO GROWTH INC SUB VTG SHS (
Aug 18, 2026 SEC
Vireo Growth Inc. announced a Normal Course Issuer Bid (NCIB) authorizing the repurchase of up to 2,426,872 subordinate
8-K — Impact 3/10
Aug 11, 2026 SEC
Vireo Growth reported Q2 2026 GAAP revenue of $209.3M (+335% YoY), massively beating the $167.4M consensus, but GAAP EPS
8-K — Impact 6/10
Aug 6, 2026 SEC
Vireo Growth Inc. (VREOF) has entered into two separate Securities Purchase Agreements to acquire all of the membership
8-K — Impact 7/10
May 15, 2026 Insider
Hussey Ross Michael was granted 115,506 shares
Director
May 15, 2026 Insider
Hussey Ross Michael was granted 96,859 shares
Director
May 15, 2026 Insider
Mancebo Victor E. was granted 96,859 shares
Director
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2023003420%
Aug 1, 2023003420%
Jul 1, 2023003420%
Jun 1, 2023003420%
Price targets
Where 1 covering analysts think VREOF trades over the next 12 months.
$45.00 +368.3% upside Strong Buy
Current$9.61 Low$45.00 Median$45.00 High$45.00 1 analysts
$45.00$45.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 2 bullish, 1 bearish, 5 mixed, 5 neutral · avg impact 5.5/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 3, 2026
ftd
FTD: VREOF — 69,984 shares ($0.8M) failed to deliver
Settlement: 20260903, Price: $10.80, FTD Value: $755,827.2, VIREO GROWTH INC SUB VTG SHS (
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$0.36$0.36–$0.36279.1%+0.0%0↑ 1↓$0.2B1
Next Q$0.39$0.39–$0.39221.5%+4.0%0↑ 1↓$0.2B1
Current FY$0.05$0.05–$0.05102.9%-75.0%0↑ 1↓$0.8B1
Next FY$1.94$1.94–$1.943780.0%+28.5%0↑ 1↓$1.1B1
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$0.360—
7d ago$0.440-0.080
30d ago$0.360—
60d ago$0.450-0.090
90d ago$0.450-0.090
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 15 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
DateInsiderTitleTypeSharesPriceValue
May 15, 2026Hussey Ross MichaelDirectorAWARD115,506——
May 15, 2026Hussey Ross MichaelDirectorAWARD96,859——
May 15, 2026Mancebo Victor E.DirectorAWARD96,859——
May 15, 2026Mancebo Victor E.DirectorAWARD115,506——
May 15, 2026Apfelbaum Sean MichaelGC and Corporate SecretaryEXERCISE133,333——
May 15, 2026Apfelbaum Sean MichaelGC and Corporate SecretaryTAX W/H39,067$0.3850$15.0K
May 15, 2026Apfelbaum Sean MichaelGC and Corporate SecretaryAWARD133,333——
May 15, 2026Nordquist Judd TheodoreDirectorAWARD115,506——
May 15, 2026Nordquist Judd TheodoreDirectorAWARD96,859——
May 15, 2026Nordquist Judd TheodoreDirectorAWARD80,000——
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VREOF.
Shares short
34,233
Settlement Sep 15, 2026
Change vs prior
+462.1%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
All VREOF filing & press-release reports (13)